TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2020 Financial Results and Business Update
TG Therapeutics (NASDAQ: TGTX) will hold a conference call on March 2, 2021, at 8:30 AM ET to discuss the fourth quarter and year-end 2020 results and provide a business outlook for 2021. The call will be hosted by Michael S. Weiss, Executive Chairman and CEO. Interested parties can join via phone or through a live webcast on the company's website. Financial results will be announced prior to the call. TG is focused on developing novel treatments for B-cell malignancies and autoimmune diseases.
- TG Therapeutics has received accelerated FDA approval for UKONIQ™ for treating certain lymphomas.
- The company has an active research pipeline with five investigational medicines.
- TG has two programs in Phase 3 development for multiple sclerosis and chronic lymphocytic leukemia.
- None.
Conference call to be held Tuesday, March 2, 2021 at 8:30 AM ET
NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Tuesday, March 2, 2021 at 8:30 AM ET to discuss results for the fourth quarter and year-end 2020 and provide a business outlook for 2021. Michael S. Weiss, Executive Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Fourth Quarter and Year End 2020 Update Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from the U.S. FDA for UKONIQ™ (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has two programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and Linkedin.
UKONIQ™ is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
When is the TG Therapeutics Q4 2020 earnings call?
What can investors expect from TG Therapeutics' March 2021 conference call?
What is TG Therapeutics known for?
Has TG Therapeutics received any FDA approvals?
What type of medicines is TG Therapeutics developing?
